SHANGHAI – Leading prescription generics maker with an up-and-coming pipeline of new chemical entities and former military research unit, Beijing Sihuan Pharmaceutical, has entered the race to find a treatment to cure the deadly Ebola virus.
SHANGHAI – A Chinese vaccine joint venture (JV), Bravovax Co. Ltd., of Wuhan, has taken on the global rights for a rotavirus vaccine to be administered to newborn infants – the first of its kind to protect infants at birth from potentially life threatening diarrhea leading to severe dehydration.
SHANGHAI – European drug companies may find it hard to bend the ear of the Chinese government on their own. The country is large with numerous stakeholders to take into account as China undertakes its massive health care reform project.
SHANGHAI – Sanofi SA, of Paris, has chosen a Shanghai address for its Asia Pacific R&D Hub. Its fifth hub, it will coordinate a complex research network across 12 Asian countries, and 50 collaborations pursuing the pharma's model of borderless, "open innovation."
SHANGHAI – European drug companies may find it hard to bend the ear of the Chinese government on their own. The country is large with numerous stakeholders to take into account as China undertakes its massive health care reform project.
SHANGHAI – Sanofi SA, of Paris, has chosen a Shanghai address for its Asia Pacific R&D Hub. Its fifth hub, it will coordinate a complex research network across 12 Asian countries, and 50 collaborations pursuing the pharma's model of borderless, "open innovation."
SHANGHAI – Getting to a $21 million series C has not been a sure thing for Eureka Therapeutics Inc., a cancer immunotherapy company based in Emeryville, Calif.
SHANGHAI – Getting to a $21 million series C has not been a sure thing for Eureka Therapeutics Inc., a cancer immunotherapy company based in Emeryville, Calif. The firm's last round of funding was six years ago, right before the financial crisis hit. But today, with cutting-edge technology that can access intracellular targets, the company finds it has become attractive to investors again.
BEIJING – The hot topic at this year's China Bio International 2014 was what type of strategy drugmakers should take to get innovative drugs on the market with China's challenging biologics manufacturing rules. It's clearly a high-stakes gamble, with innovators betting on one of three different horses to get them to the finish line.
BEIJING – The hot topic at this year's China Bio International 2014 is what type of strategy drugmakers should take to get innovative drugs on the market with China's challenging biologics manufacturing rules. It's clearly a high-stakes gamble, with innovators betting on one of three different horses to get them to the finish line.
